Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Infectious Diseases |
| Vol/bind | 201 |
| Udgave nummer | 3 |
| Sider (fra-til) | 318-30 |
| Antal sider | 13 |
| ISSN | 0022-1899 |
| DOI | |
| Status | Udgivet - 1 feb. 2010 |
Bibliografisk note
Keywords: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Poisson Distribution; Risk FactorsAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. / Worm, Signe Westring; Sabin, Caroline; Weber, Rainer; Reiss, Peter; El-Sadr, Wafaa; Dabis, Francois; De Wit, Stephane; Law, Matthew; Monforte, Antonella D'Arminio; Friis-Møller, Nina; Kirk, Ole; Fontas, Eric; Weller, Ian; Phillips, Andrew; Lundgren, Jens.
I: Journal of Infectious Diseases, Bind 201, Nr. 3, 01.02.2010, s. 318-30.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study
AU - Worm, Signe Westring
AU - Sabin, Caroline
AU - Weber, Rainer
AU - Reiss, Peter
AU - El-Sadr, Wafaa
AU - Dabis, Francois
AU - De Wit, Stephane
AU - Law, Matthew
AU - Monforte, Antonella D'Arminio
AU - Friis-Møller, Nina
AU - Kirk, Ole
AU - Fontas, Eric
AU - Weller, Ian
AU - Phillips, Andrew
AU - Lundgren, Jens
N1 - Keywords: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Poisson Distribution; Risk Factors
PY - 2010/2/1
Y1 - 2010/2/1
N2 - BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with >30,000 person-years of exposure. RESULTS. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. CONCLUSIONS. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide.
AB - BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of antiretroviral drugs, with >30,000 person-years of exposure. RESULTS. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic parameters. CONCLUSIONS. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide.
U2 - 10.1086/649897
DO - 10.1086/649897
M3 - Journal article
VL - 201
SP - 318
EP - 330
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 3
ER -